Destiny Pharma Plc operates as a clinical biotechnology company, which engages in the discovery, development and commercialization of new antimicrobial products. Its products include XF drug series, XF-73 and Pipeline. The company was founded by Suzanne Brewer, Kevin Brewer and William Guy Love on March 4, 1996 and is headquartered in Brighton, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company